877125-98-9 Usage
Uses
Used in Pharmaceutical Industry:
7-AMINOMETHYL-SPIRO[3.5]NONANE is used as a pharmacological agent for its agonistic activity at the α7 nicotinic acetylcholine receptor. This makes it a potential candidate for the development of drugs targeting this receptor subtype, which could be beneficial in treating various neurological and cognitive disorders.
Used in Anti-inflammatory Applications:
7-AMINOMETHYL-SPIRO[3.5]NONANE is used as an anti-inflammatory agent due to its potential to modulate inflammatory processes. This property could be harnessed in the development of treatments for inflammatory diseases and conditions.
Used in Neuroprotective Applications:
7-AMINOMETHYL-SPIRO[3.5]NONANE is used as a neuroprotective agent, offering potential benefits in protecting neurons from damage and degeneration. Its neuroprotective properties could be valuable in the development of therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's.
Check Digit Verification of cas no
The CAS Registry Mumber 877125-98-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,7,1,2 and 5 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 877125-98:
(8*8)+(7*7)+(6*7)+(5*1)+(4*2)+(3*5)+(2*9)+(1*8)=209
209 % 10 = 9
So 877125-98-9 is a valid CAS Registry Number.
877125-98-9Relevant academic research and scientific papers
Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-Cyanopyrimidines. Part 2
Irie, Osamu,Kosaka, Takatoshi,Kishida, Masashi,Sakaki, Junichi,Masuya, Keiichi,Konishi, Kazuhide,Yokokawa, Fumiaki,Ehara, Takeru,Iwasaki, Atsuko,Iwaki, Yuki,Hitomi, Yuko,Toyao, Atsushi,Gunji, Hiroki,Teno, Naoki,Iwasaki, Genji,Hirao, Hajime,Kanazawa, Takanori,Tanabe, Keiko,Hiestand, Peter C.,Malcangio, Marzia,Fox, Alyson J.,Bevan, Stuart J.,Yaqoob, Mohammed,Culshaw, Andrew J.,Hart, Terance W.,Hallett, Allan
scheme or table, p. 5280 - 5284 (2009/05/07)
We describe here orally active and brain-penetrant cathepsin S selective inhibitors, which are virtually devoid of hERG K+ channel affinity, yet exhibit nanomolar potency against cathepsin S and over 100-fold selectivity to cathepsin L. The new
